2019 American Society of Hematology Annual Meeting*

December 7-10, 2019; Orlando, Florida
Review slidesets and analyses of key data from the 2019 Hematology meeting.

Multiple Myeloma

Capsule Summary Slidesets

An all-oral regimen of selinexor + pomalidomide + low-dose dexamethasone appears to be safe and highly active in patients with heavily pretreated MM, warranting further evaluation.

Released: December 13, 2019

Initial results from ongoing phase I study suggest CC-93269 is safe with promising dose-dependent activity in heavily pretreated multiple myeloma.

Released: December 10, 2019

The BCMA-directed CAR T-cell therapy JNJ-4528 demonstrated manageable safety profile and robust efficacy in heavily pretreated patients with R/R MM.

Released: December 15, 2019

Long-term follow-up of LEGEND-2 suggests LCAR-B38M CAR T-cell therapy highly active in patients with relapsed/refractory multiple myeloma.

Released: December 13, 2019

The addition of daratumumab to VRd in transplant-eligible patients with MM led to significant improvement in response that deepened over time vs VRd alone.

Released: December 20, 2019

PET-negative findings at baseline portend a favorable prognosis for patients with newly diagnosed MM, as does PET and MRD double negativity postconsolidation after D-VTd and transplantation.

Released: December 19, 2019

Results from phase III study suggest no significant PFS improvement from addition of clarithromycin to Rd in newly diagnosed, transplant-ineligible patients with myeloma.

Released: December 20, 2019

Interim results from ongoing phase II study suggest ixazomib/daratumumab/dexamethasone effective in unfit or frail patients with newly diagnosed myeloma.

Released: December 13, 2019

Responses to KRd followed by ASCT, KRd consolidation, and Rd maintenance therapy associated with improved depth of response in smoldering MM.

Released: December 16, 2019

Daratumumab plus VMP demonstrates significant PFS, OS improvements vs VMP alone in transplantation-ineligible patients with newly diagnosed multiple myeloma.

Released: December 15, 2019

Daratumumab, carfilzomib, lenalidomide, and dexamethasone effective with rapid and deep responses in newly diagnosed multiple myeloma.

Released: December 10, 2019

The addition of daratumumab to triplet IRd induction therapy with modified-dose dexamethasone was associated with rapid responses that deepened over time.

Released: December 18, 2019

In patients with R/R MM, the combination of venetoclax/daratumumab/dexamethasone, with or without bortezomib, showed an acceptable safety profile and promising response rate.

Released: December 18, 2019

Initial findings from this preliminary study indicate that combined treatment with venetoclax and dexamethasone is safe and active in patients with t(11;14) R/R MM.

Released: December 17, 2019

The phase III CANDOR trial demonstrated significant PFS benefit with carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma.

Released: December 16, 2019
Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Melissa Velasquez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue